Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCR-002 in hospitalized hepatic encephalopathy
NCT01966419Phase 2Completed
- Sponsor
- Ocera Therapeutics
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in hepatic encephalopathy (HE) comparing Ornithine phenylacetate with Placebo (2 arms). Primary endpoint: Percentage of Participants in Each HE Stage. Started Jan 2014; status: completed.
02
Drugs
ornithine phenylacetate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT01966419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966419.